Volkmann ER, Tashkin DP, Sim M, et al. - Individuals recruited in the cyclophosphamide (CYC) arms of Scleroderma Lung Study (SLS) I (n = 79) and II (n = 69) were incorporated in order to contrast the safety and efficiency outcomes between the CYC arms of SLS I and II. SLS I and II CYC individuals had comparable baseline features. Subsequent to adjusting for baseline disease severity, no variation in the course of the forced vital capacity%-predicted nor the DLCO%-predicted between the SLS I and II CYC arms was noted. In both groups, treatment with CYC resulted in a notable betterment in the FVC%-prognosticated from 3 to 12 months, however, no important betterment beyond this point was seen. Treatment with CYC had no impact on the DLCO for each group. Hence, in both SLS I and II, treatment with 1 year of oral CYC resulted in comparable betterments in lung function, however, the influences were not maintained after discontinuance of CYC. Furthermore, for patients with systemic sclerosis–ILD, these results imply that extending the duration of ILD therapy could enhance outcomes.